Skip to main content
ATRC
NASDAQ Life Sciences

AtriCure Issues 2026 Revenue Guidance of $600M-$610M

feedReported by Dow Jones Newswires
Sentiment info
Neutral
Importance info
7
Price
$29.5
Mkt Cap
$1.488B
52W Low
$26.62
52W High
$43.18
Market data snapshot near publication time

summarizeSummary

AtriCure, Inc. has provided full-year 2026 revenue guidance, projecting sales to be in the range of $600 million to $610 million. This guidance follows the company's announcement of strong first-quarter 2026 financial results, as detailed in an 8-K filing earlier today. The specific revenue outlook for the full year is a critical data point for investors, offering clarity on management's expectations for future performance and serving as a key input for financial modeling. Traders will be watching subsequent earnings reports for progress against this guidance and any potential revisions.

At the time of this announcement, ATRC was trading at $29.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $26.62 to $43.18. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


show_chartPrice Chart

Share this article

Copied!

feed ATRC - Latest Insights

ATRC
May 05, 2026, 9:01 PM EDT
Filing Type: 8-K/A
Importance Score:
7
ATRC
May 05, 2026, 4:23 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
ATRC
May 05, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
ATRC
Apr 06, 2026, 11:54 AM EDT
Filing Type: DEF 14A
Importance Score:
8
ATRC
Feb 19, 2026, 12:39 PM EST
Filing Type: 10-K
Importance Score:
8
ATRC
Feb 17, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
8
ATRC
Jan 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
9